COMPARATIVE EFFICACY OF TEMOBEL AND TEMODAL DRUGS IN MULTIMODALITY TREATMENT OF HIGH-GRADE (III-IV)

V. V. Sinaiko; Синайко Валерий Васильевич; N. A. Artemova; Артемова Н. А.; T. L. Yurkshtovich; Юркштович Т. Л.; P. M. Bychkovsky; Бычковский П. М.; K. A. Frolenkov; Фроленков К. А.

doi:10.17650/1726-9784-2015-14-2-59-64

COMPARATIVE EFFICACY OF TEMOBEL AND TEMODAL DRUGS IN MULTIMODALITY TREATMENT OF HIGH-GRADE (III-IV)

Authors: Sinaiko V.V.¹, Artemova N.A.¹, Yurkshtovich T.L.², Bychkovsky P.M.³, Frolenkov K.A.⁴
Affiliations:
1. ГУ «РНПЦ онкологии и медицинской радиологии им. Н.Н. Александрова»
2. Учреждение Белорусского государственного университета «Научно-исследовательский институт физико-химических проблем»
3. Учебно-научно-производственное республиканское унитарное предприятие «Унитехпром БГУ»
4. Республиканское унитарное предприятие «Белмедпрепараты»
Issue: Vol 14, No 2 (2015)
Pages: 59-64
Section: ORIGINAL REPORTS
Published: 30.06.2015
URL: https://bioterapevt.abvpress.ru/jour/article/view/19
DOI: https://doi.org/10.17650/1726-9784-2015-14-2-59-64
ID: 19

Cite item

Full Text

Open Access
Restricted Access

Access granted
Restricted Access

Subscription or Fee Access

Abstract
About the authors
References
Supplementary files
Statistics

Abstract

An open-label, retrospective comparative clinical trial evaluated the efficacy of Temobel (RUP Belmedpreparaty) and Temodal (Schering-Plough, the Office of the Joint-Stock Company «Schering-Plough Central East AG») in 90 patients with high-grade (III-IV) glial brain tumors within a postoperative chemoradiotherapy course (a total target dose of 50-60 Gy). The compared groups, 45 patients in each, were fully matchable in prognostic factors affecting treatment outcomes. Median survival, 1- and 3-year overall survivals with Temobel in the combination treatment scheme were 20 months, 72.7±6.7% and 23.7±9.5%, whereas with Temodal they were 17 months, 77.8±6.2% and 30.3±7.0% respectively (P=0.935). Meanwhile, progressive-free median survival and progressive-free 1- and 3-year survival with Temobel and Temodal were 12 months, 51.0±7.5%, 21.3±6.4% and 11 months, 49.3±7.6%, 15.5±5,7% respectively (P=0.814). No statistically significant differences were found in the survival of patients in the compared groups.

Keywords

высокозлокачественные глиомы, химиолучевая терапия, Темобел, Темодал, high-grade gliomas, chemoradiotherapy, Temobel, Temodal

References

Supplementary files

Supplementary Files

Action

1. JATS XML

Download

Username
Password
Remember me

Forgot password?	Register

Username
Password
Remember me

Forgot password?	Register

COMPARATIVE EFFICACY OF TEMOBEL AND TEMODAL DRUGS IN MULTIMODALITY TREATMENT OF HIGH-GRADE (III-IV)

Full Text

Abstract

Keywords

About the authors

V. V. Sinaiko

N. A. Artemova

T. L. Yurkshtovich

P. M. Bychkovsky

K. A. Frolenkov

References

Supplementary files